SCYNEXIS Inc (SCYX) stock
SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3072% below fair value
$2.85−0.06 (-2.06%)
Close on Nov 17, 2026Market cap $28.36MP/E –Yield –
Scynexis price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Scynexis's price to sales ratio was 1.8× on Nov 11, 2026, against 9.9× a year earlier. Over the last 5 years it ranged from 0.4× to 37.5×, with a median of 8.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.8× | −7.3 |
| 2025 | Dec 31, 2025 | 9.0× | +3.7 |
| 2024 | Dec 31, 2024 | 5.4× | +4.7 |
| 2023 | Dec 29, 2023 | 0.6× | −11.6 |
| 2022 | Dec 30, 2022 | 12.2× | +0.6 |
| 2021 | Dec 31, 2021 | 11.6× | −256.0 |
| 2020 | Jan 31, 2020 | 267.6× | −14.6 |
| 2019 | Dec 31, 2019 | 282.2× | +193.4 |
| 2018 | Dec 31, 2018 | 88.8× | −167.0 |
| 2017 | Dec 29, 2017 | 255.8× | −36.2 |
| 2016 | Dec 30, 2016 | 292.0× | +223.3 |
| 2015 | Dec 31, 2015 | 68.7× | +58.7 |
| 2014 | Dec 31, 2014 | 10.0× | – |
See a number that looks wrong?